A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation

Inclusion Criteria: * Recurrent locally advanced and/or metastatic hepatocellular carcinoma (HCC) post liver transplantation * Life expectancy of 3 months or greater * Have measurable disease by the revised response evaluation criteria in solid tumors (mRECIST) * History of positive test for hepatitis B virus surface antigen (HBsAg) * Expression of LioCyxTM target epitopes within specific human leukocyte antigen (HLA) class I profile * Had received treatment with at least one standard therapy or refused, appropriate approved therapy for their disease * 21 years of age or older * Eastern Cooperative Oncology Group (ECOG) performance status ≤1 * Willing and able to comply with all study procedures Exclusion Criteria: * Known, clinically suspected or has history of central nervous system (CNS) and bone metastasis * Tumor burden in the liver exceeding 70% * Significant ongoing immunologic rejection based on pathology and clinical diagnosis * Evidence or history of significant bleeding diathesis or coagulopathy * Prior exposure to any cell therapy such as, but not limited to NK, CIK, DC, CTL, stem cells therapy * Known history of testing positive for human immunodeficiency virus (HIV) 1 or 2 or known acquired immunodeficiency syndrome (AIDS) * Lack of peripheral venous or central venous access or any condition that would interfere with drug administration or collection of study samples * Women who are pregnant or breast-feeding